Using biotechnology as a forensic foundation, Applied DNA Sciences creates unique security solutions addressing the challenges of modern commerce. Whether for supply chain security, brand protection or law enforcement applications, it is our goal to help establish secure flourishing environments that foster quality, integrity and success.
With secure taggants, high-resolution DNA authentication, and comprehensive reporting, our plant-based DNA technologies are designed to deliver what we believe to be the greatest levels of security, deterrence and legal recourse strength. We are also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction (“PCR”).
James A. Hayward, Phd., Sc.D
Chairman of the Board, President and Chief Executive Officer
Chief Financial Officer
Chief Information Officer
Brian Kintslinger, CFA
Applied DNA Sciences. Inc. is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Applied DNA’s performance made by the analyst(s) are theirs alone and do not represent opinions, forecasts or predictions of Applied DNA or its management. Applied DNA does not by its reference above imply its endorsement of or concurrence with such information, conclusions or recommendations. This list includes analyst(s) currently known by Applied DNA to follow the company, but may not be complete and may change as firms add or delete coverage. Applied DNA does not undertake any duty to update this information or any information provided by third parties.
Pepper Hamilton LLP
New York Times Building
620 Eighth Avenue/37th Floor
New York, New York 10018-1405
Applied DNA Sciences is not able to purchase shares on your behalf, and it is not possible for you to purchase shares directly from us. Please contact a stockbroker, bank, or independent financial advisor, who should be able to act on your behalf.
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 14, 2015, and our subsequent quarterly reports on Form 10-Q, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.
Events and Presentations
March 11-13, 2018 | ROTH Capital Markets’ 30th Annual Conference | Dana Point, CA
February 8, 2018 |Applied DNA Sciences Fiscal 2018 First Quarter Financial Results| Stony Brook, N.Y.
December 28, 2017 | Applied DNA Sciences Fiscal Fourth Quarter 2017 Conference Call | Stony Brook, NY
Archived Webcast: https://services.choruscall.com/links/apdn171205.html
Conference Replay Information (available 1hr after call ends)
Replay Access Code: 10113295
International Dial-in: 1-412-317-0088
*Replay End Date: December 29, 2017
August 10, 2017 | Applied DNA Sciences Fiscal Third Quarter 2017 Conference Call | Stony Brook, NY
Archived webcast of earnings conference call (audio and slide presentation): https://services.choruscall.com/links/apdn170810.html